This means that VC alone, even at a high dose, is effective in inducing a potent oxidative stress in KRAS-mutant cancer cells and reaching a potent cytotoxic impact in clinical settings that might not be feasible consistently because of DHA’s competition with glucose. The gene discussed is KRAS; the disease is cancer.